VSTM vs XENE: fair value comparison
Verastem, Inc. and Xenon Pharmaceuticals Inc. · Updated 2026-10-19
VSTM has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. XENE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, VSTM currently ranks higher by quality score.
| VSTM | XENE | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $8.65 | $33.49 |
| 12-month range | $3.45–$10.64 | $33.49–$70.96 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #275 of 301 Healthcare | #276 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | High | Low |
| Margin trend | Contracting | Expanding |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Uptrend | Downtrend |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: VSTM fair value analysis · XENE fair value analysis